Advanced Enzyme Technologies Limited

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ASIANPAINT.NS has a market cap of 2.3T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ASIANPAINT.NS trades at ₹2,448.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ASIANPAINT.NS's P/E ratio is 61.04. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ASIANPAINT.BO has a market cap of 2.3T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ASIANPAINT.BO trades at ₹2,447.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ASIANPAINT.BO's P/E ratio is 60.78. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PIDILITIND.NS has a market cap of 1.4T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PIDILITIND.NS trades at ₹1,364.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PIDILITIND.NS's P/E ratio is 61.47. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.NS's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PIDILITIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PIDILITIND.BO has a market cap of 1.4T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PIDILITIND.BO trades at ₹1,364.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PIDILITIND.BO's P/E ratio is 61.19. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.BO's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PIDILITIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SOLARINDS.NS has a market cap of 1.4T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SOLARINDS.NS trades at ₹15,459.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SOLARINDS.NS's P/E ratio is 96.27. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.NS's ROE of +0.32%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOLARINDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SOLARINDS.BO has a market cap of 1.4T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SOLARINDS.BO trades at ₹15,452.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SOLARINDS.BO's P/E ratio is 95.94. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.BO's ROE of +0.32%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOLARINDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SRF.NS has a market cap of 748.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SRF.NS trades at ₹2,551.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SRF.NS's P/E ratio is 42.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SRF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SRF.BO has a market cap of 748.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SRF.BO trades at ₹2,551.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SRF.BO's P/E ratio is 42.07. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SRF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, LINDEINDIA.BO has a market cap of 626.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while LINDEINDIA.BO trades at ₹7,437.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas LINDEINDIA.BO's P/E ratio is 105.86. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.BO's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, LINDEINDIA.NS has a market cap of 626.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while LINDEINDIA.NS trades at ₹7,443.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas LINDEINDIA.NS's P/E ratio is 105.92. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.NS's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BERGEPAINT.NS has a market cap of 549.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BERGEPAINT.NS trades at ₹470.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BERGEPAINT.NS's P/E ratio is 52.28. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BERGEPAINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BERGEPAINT.BO has a market cap of 548.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BERGEPAINT.BO trades at ₹470.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BERGEPAINT.BO's P/E ratio is 50.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BERGEPAINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, FLUOROCHEM.BO has a market cap of 394.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while FLUOROCHEM.BO trades at ₹3,747.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas FLUOROCHEM.BO's P/E ratio is 60.04. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FLUOROCHEM.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FLUOROCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FLUOROCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, HSCL.NS has a market cap of 307B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while HSCL.NS trades at ₹609.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas HSCL.NS's P/E ratio is 40.46. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, HSCL.BO has a market cap of 306.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while HSCL.BO trades at ₹610.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas HSCL.BO's P/E ratio is 40.37. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ACUTAAS.NS has a market cap of 212.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ACUTAAS.NS trades at ₹2,676.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ACUTAAS.NS's P/E ratio is 74.02. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.NS's ROE of +0.21%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ACUTAAS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ACUTAAS.BO has a market cap of 209.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ACUTAAS.BO trades at ₹2,675.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ACUTAAS.BO's P/E ratio is 73.07. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ACUTAAS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ATUL.NS has a market cap of 200.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ATUL.NS trades at ₹6,949.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ATUL.NS's P/E ratio is 29.62. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ATUL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ATUL.BO has a market cap of 200.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ATUL.BO trades at ₹6,937.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ATUL.BO's P/E ratio is 33.74. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ATUL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, DCMSHRIRAM.BO has a market cap of 191.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while DCMSHRIRAM.BO trades at ₹1,251.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas DCMSHRIRAM.BO's P/E ratio is 28.85. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to DCMSHRIRAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, DCMSHRIRAM.NS has a market cap of 188.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while DCMSHRIRAM.NS trades at ₹1,252.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas DCMSHRIRAM.NS's P/E ratio is 28.43. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to DCMSHRIRAM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AARTIIND.NS has a market cap of 183.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AARTIIND.NS trades at ₹513.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AARTIIND.NS's P/E ratio is 48.75. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.NS's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AARTIIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AARTIIND.BO has a market cap of 183.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AARTIIND.BO trades at ₹513.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AARTIIND.BO's P/E ratio is 48.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.BO's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AARTIIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, KANSAINER.BO has a market cap of 159.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while KANSAINER.BO trades at ₹196.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas KANSAINER.BO's P/E ratio is 27.22. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, KANSAINER.NS has a market cap of 158.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while KANSAINER.NS trades at ₹196.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas KANSAINER.NS's P/E ratio is 27.07. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BASF.NS has a market cap of 157.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BASF.NS trades at ₹3,649.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BASF.NS's P/E ratio is 41.63. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BASF.BO has a market cap of 157.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BASF.BO trades at ₹3,651.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BASF.BO's P/E ratio is 41.82. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AETHER.NS has a market cap of 155.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AETHER.NS trades at ₹1,252.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AETHER.NS's P/E ratio is 72.23. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AETHER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AETHER.BO has a market cap of 155.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AETHER.BO trades at ₹1,252.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AETHER.BO's P/E ratio is 71.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AETHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ANURAS.NS has a market cap of 152.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ANURAS.NS trades at ₹1,348.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ANURAS.NS's P/E ratio is 87.11. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.NS's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ANURAS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ANURAS.BO has a market cap of 151.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ANURAS.BO trades at ₹1,348.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ANURAS.BO's P/E ratio is 86.98. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.BO's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ANURAS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SPLPETRO.BO has a market cap of 142.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SPLPETRO.BO trades at ₹742.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SPLPETRO.BO's P/E ratio is 43.12. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SPLPETRO.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SPLPETRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SPLPETRO.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, FINEORG.BO has a market cap of 142B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while FINEORG.BO trades at ₹4,604.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas FINEORG.BO's P/E ratio is 35.75. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FINEORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, FINEORG.NS has a market cap of 141.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while FINEORG.NS trades at ₹4,597.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas FINEORG.NS's P/E ratio is 35.73. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FINEORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, VINATIORGA.NS has a market cap of 137.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while VINATIORGA.NS trades at ₹1,335.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas VINATIORGA.NS's P/E ratio is 31.02. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.NS's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, VINATIORGA.BO has a market cap of 137.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while VINATIORGA.BO trades at ₹1,333.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas VINATIORGA.BO's P/E ratio is 30.99. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.BO's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AKZOINDIA.NS has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AKZOINDIA.NS trades at ₹2,986.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AKZOINDIA.NS's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.NS's ROE of +1.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AKZOINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AKZOINDIA.BO has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AKZOINDIA.BO trades at ₹2,985.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AKZOINDIA.BO's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.BO's ROE of +1.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AKZOINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PRIVISCL.BO has a market cap of 131.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PRIVISCL.BO trades at ₹3,367.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PRIVISCL.BO's P/E ratio is 43.58. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.BO's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PRIVISCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRIVISCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PRIVISCL.NS has a market cap of 131B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PRIVISCL.NS trades at ₹3,362.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PRIVISCL.NS's P/E ratio is 43.60. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.NS's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO and PRIVISCL.NS have similar daily volatility (3.68).Check PRIVISCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SHAILY.BO has a market cap of 116.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SHAILY.BO trades at ₹2,588.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SHAILY.BO's P/E ratio is 73.97. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SHAILY.BO's ROE of +0.28%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SHAILY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SHAILY.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PCBL.BO has a market cap of 114B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PCBL.BO trades at ₹309.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PCBL.BO's P/E ratio is 42.92. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.BO's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PCBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PCBL.NS has a market cap of 113.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PCBL.NS trades at ₹309.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PCBL.NS's P/E ratio is 42.69. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.NS's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PCBL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JUBLINGREA.BO has a market cap of 112.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JUBLINGREA.BO trades at ₹717.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JUBLINGREA.BO's P/E ratio is 42.58. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINGREA.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLINGREA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINGREA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AMIORG.NS has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AMIORG.NS trades at ₹1,176.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AMIORG.NS's P/E ratio is 119.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, AMIORG.BO has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while AMIORG.BO trades at ₹1,176.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas AMIORG.BO's P/E ratio is 118.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GRWRHITECH.NS has a market cap of 92.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GRWRHITECH.NS trades at ₹4,271.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GRWRHITECH.NS's P/E ratio is 30.23. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GRWRHITECH.BO has a market cap of 92.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GRWRHITECH.BO trades at ₹4,271.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GRWRHITECH.BO's P/E ratio is 30.10. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, CLEAN.BO has a market cap of 87.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while CLEAN.BO trades at ₹820.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas CLEAN.BO's P/E ratio is 35.62. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to CLEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, CLEAN.NS has a market cap of 87.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while CLEAN.NS trades at ₹819.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas CLEAN.NS's P/E ratio is 35.52. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to CLEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ALKYLAMINE.BO has a market cap of 77.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ALKYLAMINE.BO trades at ₹1,579.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ALKYLAMINE.BO's P/E ratio is 42.93. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ALKYLAMINE.NS has a market cap of 77.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ALKYLAMINE.NS trades at ₹1,579.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ALKYLAMINE.NS's P/E ratio is 42.82. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SUDARSCHEM.NS has a market cap of 72.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SUDARSCHEM.NS trades at ₹943.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SUDARSCHEM.NS's P/E ratio is -116.67. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.NS's ROE of -0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SUDARSCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, SUDARSCHEM.BO has a market cap of 71.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while SUDARSCHEM.BO trades at ₹942.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas SUDARSCHEM.BO's P/E ratio is 135.18. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.BO's ROE of -0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SUDARSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GALAXYSURF.NS has a market cap of 66.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GALAXYSURF.NS trades at ₹1,863.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GALAXYSURF.NS's P/E ratio is 23.58. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GALAXYSURF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GALAXYSURF.BO has a market cap of 65.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GALAXYSURF.BO trades at ₹1,864.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GALAXYSURF.BO's P/E ratio is 23.39. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GALAXYSURF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, KINGFA.NS has a market cap of 65B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while KINGFA.NS trades at ₹4,731.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas KINGFA.NS's P/E ratio is 37.61. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KINGFA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, KINGFA.BO has a market cap of 64.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while KINGFA.BO trades at ₹4,745.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas KINGFA.BO's P/E ratio is 37.40. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KINGFA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, TANFACIND.BO has a market cap of 50.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while TANFACIND.BO trades at ₹2,444.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas TANFACIND.BO's P/E ratio is 67.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TANFACIND.BO's ROE of +0.25%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to TANFACIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TANFACIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GULFOILLUB.BO has a market cap of 48.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GULFOILLUB.BO trades at ₹979.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GULFOILLUB.BO's P/E ratio is 14.08. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.BO's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GULFOILLUB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GULFOILLUB.NS has a market cap of 48.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GULFOILLUB.NS trades at ₹977.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GULFOILLUB.NS's P/E ratio is 14.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.NS's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GULFOILLUB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BALAMINES.NS has a market cap of 43.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BALAMINES.NS trades at ₹1,455.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BALAMINES.NS's P/E ratio is 30.11. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.NS's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, BALAMINES.BO has a market cap of 43.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while BALAMINES.BO trades at ₹1,453.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas BALAMINES.BO's P/E ratio is 30.02. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.BO's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, NEOGEN.BO has a market cap of 43.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while NEOGEN.BO trades at ₹1,687.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas NEOGEN.BO's P/E ratio is 218.57. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.BO's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, NEOGEN.NS has a market cap of 43B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while NEOGEN.NS trades at ₹1,686.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas NEOGEN.NS's P/E ratio is 217.91. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, RESPONIND.NS has a market cap of 42.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while RESPONIND.NS trades at ₹157.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas RESPONIND.NS's P/E ratio is 23.47. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to RESPONIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, POCL.NS has a market cap of 42.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while POCL.NS trades at ₹1,374.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas POCL.NS's P/E ratio is 36.93. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, POCL.BO has a market cap of 42.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while POCL.BO trades at ₹1,374.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas POCL.BO's P/E ratio is 36.89. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, RESPONIND.BO has a market cap of 41.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while RESPONIND.BO trades at ₹157.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas RESPONIND.BO's P/E ratio is 23.23. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to RESPONIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, INDIGOPNTS.BO has a market cap of 41.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while INDIGOPNTS.BO trades at ₹855.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas INDIGOPNTS.BO's P/E ratio is 28.59. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to INDIGOPNTS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, INDIGOPNTS.NS has a market cap of 41.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while INDIGOPNTS.NS trades at ₹856.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas INDIGOPNTS.NS's P/E ratio is 28.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to INDIGOPNTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, LXCHEM.BO has a market cap of 40.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while LXCHEM.BO trades at ₹144.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas LXCHEM.BO's P/E ratio is 50.70. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LXCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, VISHNU.BO has a market cap of 40.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while VISHNU.BO trades at ₹616.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas VISHNU.BO's P/E ratio is 29.09. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to VISHNU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, LXCHEM.NS has a market cap of 40.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while LXCHEM.NS trades at ₹145.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas LXCHEM.NS's P/E ratio is 50.46. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LXCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, VISHNU.NS has a market cap of 40.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while VISHNU.NS trades at ₹617.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas VISHNU.NS's P/E ratio is 28.97. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to VISHNU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ADVENZYMES.NS has a market cap of 38.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ADVENZYMES.NS trades at ₹353.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ADVENZYMES.NS's P/E ratio is 25.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ADVENZYMES.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ADVENZYMES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ADVENZYMES.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JINDALPOLY.NS has a market cap of 31.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JINDALPOLY.NS trades at ₹720.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JINDALPOLY.NS's P/E ratio is -14.93. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.NS's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JINDALPOLY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JINDALPOLY.BO has a market cap of 31.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JINDALPOLY.BO trades at ₹717.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JINDALPOLY.BO's P/E ratio is -24.41. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.BO's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JINDALPOLY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GRAUWEIL.BO has a market cap of 31.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GRAUWEIL.BO trades at ₹69.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GRAUWEIL.BO's P/E ratio is 22.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GRAUWEIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, GRAUWEIL.NS has a market cap of 31.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while GRAUWEIL.NS trades at ₹69.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas GRAUWEIL.NS's P/E ratio is 22.48. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRAUWEIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, TATVA.BO has a market cap of 30.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while TATVA.BO trades at ₹1,305.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas TATVA.BO's P/E ratio is 93.69. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TATVA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, TATVA.NS has a market cap of 30.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while TATVA.NS trades at ₹1,307.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas TATVA.NS's P/E ratio is 93.37. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TATVA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PREMEXPLN.BO has a market cap of 30.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PREMEXPLN.BO trades at ₹556.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PREMEXPLN.BO's P/E ratio is 69.46. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PREMEXPLN.NS has a market cap of 30.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PREMEXPLN.NS trades at ₹555.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PREMEXPLN.NS's P/E ratio is 69.86. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, NOCIL.NS has a market cap of 30.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while NOCIL.NS trades at ₹190.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas NOCIL.NS's P/E ratio is 50.56. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NOCIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, NOCIL.BO has a market cap of 29.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while NOCIL.BO trades at ₹190.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas NOCIL.BO's P/E ratio is 47.47. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.BO's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NOCIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, POLYPLEX.NS has a market cap of 29.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while POLYPLEX.NS trades at ₹940.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas POLYPLEX.NS's P/E ratio is 98.39. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.NS's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to POLYPLEX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, POLYPLEX.BO has a market cap of 29.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while POLYPLEX.BO trades at ₹939.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas POLYPLEX.BO's P/E ratio is 98.08. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.BO's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to POLYPLEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, PRINCEPIPE.NS has a market cap of 28.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while PRINCEPIPE.NS trades at ₹261.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas PRINCEPIPE.NS's P/E ratio is 65.98. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRINCEPIPE.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PRINCEPIPE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRINCEPIPE.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ROSSARI.BO has a market cap of 26.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ROSSARI.BO trades at ₹480.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ROSSARI.BO's P/E ratio is 17.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ROSSARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, ROSSARI.NS has a market cap of 26.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while ROSSARI.NS trades at ₹479.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas ROSSARI.NS's P/E ratio is 17.70. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ROSSARI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, DDEVPLSTIK.BO has a market cap of 26.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while DDEVPLSTIK.BO trades at ₹251.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas DDEVPLSTIK.BO's P/E ratio is 13.10. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DDEVPLSTIK.BO's ROE of +0.31%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to DDEVPLSTIK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DDEVPLSTIK.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JUBLCPL.BO has a market cap of 26B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JUBLCPL.BO trades at ₹1,691.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JUBLCPL.BO's P/E ratio is 21.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLCPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, DDEVPLSTIK.NS has a market cap of 26B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while DDEVPLSTIK.NS trades at ₹251.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas DDEVPLSTIK.NS's P/E ratio is 13.08. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DDEVPLSTIK.NS's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to DDEVPLSTIK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DDEVPLSTIK.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JUBLINDS.NS has a market cap of 25.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JUBLINDS.NS trades at ₹1,633.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JUBLINDS.NS's P/E ratio is 72.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINDS.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLINDS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINDS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JUBLCPL.NS has a market cap of 25.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JUBLCPL.NS trades at ₹1,691.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JUBLCPL.NS's P/E ratio is 21.05. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.NS's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLCPL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, JUBLINDS.BO has a market cap of 25.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while JUBLINDS.BO trades at ₹1,623.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas JUBLINDS.BO's P/E ratio is 72.31. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINDS.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLINDS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINDS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, TIDEWATER.NS has a market cap of 25.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while TIDEWATER.NS trades at ₹1,479.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas TIDEWATER.NS's P/E ratio is 16.90. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TIDEWATER.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TIDEWATER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TIDEWATER.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 38.8B. In comparison, TIDEWATER.BO has a market cap of 25.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹353.80, while TIDEWATER.BO trades at ₹1,478.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 25.52, whereas TIDEWATER.BO's P/E ratio is 16.90. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TIDEWATER.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TIDEWATER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TIDEWATER.BO's competition here